Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000175" target="_blank" >RIV/00064173:_____/19:N0000175 - isvavai.cz</a>
Výsledek na webu
<a href="https://doi.org/10.4158/EP-2018-0311" target="_blank" >https://doi.org/10.4158/EP-2018-0311</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4158/EP-2018-0311" target="_blank" >10.4158/EP-2018-0311</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist
Popis výsledku v původním jazyce
The manuscript summarizes current consensual view of bone specialists and a nephrologist of the management of osteoporosis in patients with advanced chronic kidney disease (CKD) as a part of CKD-MBD (mineral and bone disorder associated with CKD). Osteoporosis has been recently accepted as a subunit of CKD-MBD, occurring in up to one third of advanced CKD patients, with fractures being the most severe complication. Diagnosis and differential diagnosis is currently based on non-invasive procedures (densitometry, laboratory assessment of calcium-phosphate metabolism and bone turnover); originally recommended bone biopsy is reserved for unclear cases. Specific treatment is complicated since majority of anti-osteoporotic drugs are contraindicated in advanced CKD and all of them lack robust data on effectiveness and safety in this specific population.
Název v anglickém jazyce
Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist
Popis výsledku anglicky
The manuscript summarizes current consensual view of bone specialists and a nephrologist of the management of osteoporosis in patients with advanced chronic kidney disease (CKD) as a part of CKD-MBD (mineral and bone disorder associated with CKD). Osteoporosis has been recently accepted as a subunit of CKD-MBD, occurring in up to one third of advanced CKD patients, with fractures being the most severe complication. Diagnosis and differential diagnosis is currently based on non-invasive procedures (densitometry, laboratory assessment of calcium-phosphate metabolism and bone turnover); originally recommended bone biopsy is reserved for unclear cases. Specific treatment is complicated since majority of anti-osteoporotic drugs are contraindicated in advanced CKD and all of them lack robust data on effectiveness and safety in this specific population.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30202 - Endocrinology and metabolism (including diabetes, hormones)
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Endocrine Practice
ISSN
1530-891X
e-ISSN
1934-2403
Svazek periodika
25
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
4
Strana od-do
193-196
Kód UT WoS článku
000460130000009
EID výsledku v databázi Scopus
2-s2.0-85062384143